Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Intron A

(interferon)

Phase 3Small molecule

Interferon is used to treat certain viral infections like hepatitis C and some cancers by helping the immune system fight disease. It can also be used for multiple sclerosis to reduce the frequency of relapses.[1] Intron A is currently being investigated across 20 indications[3], with its most advanced program in Phase 3.[1]

Intron A is one of 508 small molecule programs targeting Granuloma. It is currently in Phase 3.

20

Indications

24

Total Trials

3

Active Trials

507

Competitors

Pipeline

Status by Indication[3][1]

Indication

GranulomaActive, not recruiting

Hepatitis B Virus InfectionActive, not recruiting

LymphomaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Zollinger-Ellison SyndromeActive, not recruiting

Chronic HepatitisActive, not recruiting

Malignant Colon NeoplasmActive, not recruiting

Chronic Hepatitis B Virus InfectionActive, not recruiting

Islet Cell TumorActive, not recruiting

Interstitial CystitisActive, not recruiting

GranulomaPhase 2

Active, not recruiting

Hepatitis B Virus InfectionPreclinical

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

Metastatic MelanomaPhase 1/Phase 2

Active, not recruiting

Zollinger-Ellison SyndromePhase 2

Active, not recruiting

Chronic HepatitisPreclinical

Active, not recruiting

Malignant Colon NeoplasmPhase 3

Active, not recruiting

Chronic Hepatitis B Virus InfectionPreclinical

Active, not recruiting

Islet Cell TumorPhase 2

Active, not recruiting

Interstitial CystitisPhase 2/Phase 3

Active, not recruiting

Showing 10 of 20 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Intron A

Blenoxane

SSequus Pharmaceuticals

Velban

EEastern Cooperative Oncology Group

Oncaspar

Zofran

Norvir

Wellcovorin

GGlaxo Dba Glaxosmithkline

Tafasitamab

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Nuvigil

NNuvo Research GmbH

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

HBV Infection

NCT06503796

Phase 3Recruiting

Acute Myeloid Leukemia

NCT06802718

Q2 2029

Phase 1Not yet recruiting

Immunotherapy

NCT07199413

Clinical

Trials by Indication[1]

Chronic Hepatitis7 trials

A Cohort Study on Long-term Clinical Outcomes of Antiviral Therapy in Patients With Chronic Hepatitis B and Cirrhosis

Unknown status·—··NCT04301908·10,000 enrolled

Cohort Study of Efficacy and Safety of Interferon Intermittent Treatment of Chronic Hepatitis B

Completed·—··NCT04028856·400 enrolled

The Curative Effect and Security of Interferon Combined Resveratrol on HBeAg Positive Chronic Hepatitis B Patients

Completed·TThe First Hospital of Jilin University·N/A·NCT03546530·228 enrolled

Show 4 more trials

Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B

Unknown status·SSun Yat-sen University·N/A·NCT00860626·50 enrolled

An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C

Unknown status·—··NCT04301882·1,000 enrolled

Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C

Unknown status·—··NCT04071353·1,000 enrolled

Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy

Unknown status·—··NCT05792878·600 enrolled

Multiple Sclerosis2 trials

Characteristic Study on Chinese Patients With Multiple Sclerosis

Unknown status·SSun Yat-sen University·N/A·NCT00818103·600 enrolled

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Completed· Sanofi logo

Sanofi·Phase 2·NCT00489489·118 enrolled

HCV1 trial

Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease

Completed·TThe First Hospital of Jilin University·Phase 1/2·NCT01605513·80 enrolled

Acute Lymphoblastic Leukemia1 trial

Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT00763763·55 enrolled

Lymphoma1 trial

Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00577993·210 enrolled

12 more indications

Acute Myeloid Leukemia1 trial

Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia

Recruiting·PPeking University People's Hospital·Phase 3·NCT06802718·96 enrolled

Immunotherapy1 trial

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

Not yet recruiting·MMedical College of Wisconsin·Phase 1·NCT07199413·20 enrolled

Monotherapy1 trial

Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia

Completed·PPETHEMA Foundation·Phase 4·NCT00390897·360 enrolled

Interstitial Cystitis1 trial

Assessing the Effectiveness and Safety of Interferon Bladder Infusion for the Treatment of Interstitial Cystitis

Unknown status·WWest China Hospital·Phase 2/3·NCT05912946·129 enrolled

Zollinger-Ellison Syndrome1 trial

Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00001228·50 enrolled

Chronic HBV Infection1 trial

Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention

Unknown status·—··NCT04030039·420 enrolled

Melanoma1 trial

A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT01782508·40 enrolled

HBV Infection1 trial

Antiviral Therapy in Infants With HBV Infection

Not yet recruiting·—·Phase 4·NCT06503796·60 enrolled

Metastatic Melanoma1 trial

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT01409187

Granuloma1 trial

Treatment and Natural History Study of Lymphomatoid Granulomatosis

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001379·94 enrolled

Renal Cell Carcinoma1 trial

BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

Completed· Bayer logo

Bayer·Phase 2·NCT00117637·189 enrolled

Chronic Lymphocytic Leukemia1 trial

Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT00962715

Sources

References

[1]
ClinicalTrials.gov — 24 trial records for interferon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — interferon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for interferon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Related News